Total trials
36
Active
6
Phase 3
1
Total enrollment
8,909
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Subcutaneous Triptorelin | — | — | — | — | — | 1 | |
| Intranasal nafarelin | — | — | — | — | — | 1 | |
| 10 mcg of follitropin-delta + 150 of hMG | — | — | — | — | — | 1 | |
| 5 mcg of follitropin-delta + 225 of hMG | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 |
Next readouts
- 2027-02
- 2028-01-15
- 2029-02
Top conditions
- Infertility19
- Oocyte Donation3
- Polycystic Ovary Syndrome2
- Preimplantation Genetic Screening2
- Fertility Preservation2
- Embryo Transfer2
- Progesterone2
- Infertility, Female2
Frequently asked questions about Fundacion Dexeus
- How many clinical trials does Fundacion Dexeus have on ClinicalTrials.gov?
- Fundacion Dexeus is listed as the lead sponsor on 36 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fundacion Dexeus's trials are in Phase 3?
- 1 of Fundacion Dexeus's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Fundacion Dexeus focus on?
- Fundacion Dexeus's most-studied conditions on ClinicalTrials.gov are Infertility, Oocyte Donation, Polycystic Ovary Syndrome, Preimplantation Genetic Screening, Fertility Preservation.
- When are Fundacion Dexeus's next clinical trial readouts?
- Fundacion Dexeus has 3 upcoming primary-completion readouts tracked here; the soonest is “Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.”, expected around 2027-02.